Gene Kennedy, MD
Galera Therapeutics · NewLink Genetics Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gene Kennedy, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:10 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03689712 · ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer PatientsGalera Therapeutics, Inc. · completed · Oral Mucositis · study chair
- Ph1/Ph2NCT03340974 · Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic CancerGalera Therapeutics, Inc. · completed · Pancreatic Cancer, Stereotactic Body Radiation Therapy · study chair
- Ph1NCT02502708 · Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsNewLink Genetics Corporation · completed · Glioblastoma Multiforme, Glioma, Gliosarcoma · study director
- Ph1NCT02460367 · Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung CancerNewLink Genetics Corporation · terminated · Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.